Mercury Laboratories 45th Annual Report FY26

Revenue from Operations: ₹7,593.67 lakhs (1.10% growth from FY25: ₹7,510.12 lakhs)
Profit Before Tax: ₹663.72 lakhs (42.38% growth from FY25: ₹466.17 lakhs)
Net Profit After Tax: ₹483.40 lakhs (53.71% growth from FY25: ₹314.49 lakhs)
Earnings Per Share (Basic & Diluted): ₹40.28 (FY25: ₹26.21)
Export Revenue: ₹2,472.32 lakhs (18.62% growth from FY25: ₹2,084.29 lakhs)
Domestic Revenue: ₹5,121.35 lakhs (5.61% decline from FY25: ₹5,425.83 lakhs)
Total Assets: ₹7,908.22 lakhs (FY25: ₹7,423.52 lakhs)
Equity Share Capital: ₹120.00 lakhs (unchanged)
Reserves & Surplus: ₹5,687.63 lakhs (FY25: ₹5,236.92 lakhs)

Recommended final dividend of ₹3.50 per equity share of ₹10 each for FY 2025-26
Total dividend payout: ₹42.00 lakhs
Record date: September 21, 2026
Payment date: On or before October 27, 2026

Date: September 28, 2026
Time: 11:30 AM IST
Mode: Video Conferencing/Other Audio-Visual Means (VC/OAVM)
Cut-off date for voting: September 21, 2026
E-voting period: September 24, 2026 (9:00 AM) to September 27, 2026 (5:00 PM)
Book closure: September 22, 2026 to September 28, 2026 (both days inclusive)

Directors as on March 31, 2026:

Key Managerial Personnel:

Board Meetings: 4 meetings held during FY 2025-26

Ordinary Business:

1. Adoption of audited financial statements for FY 2025-26

2. Declaration of dividend of ₹3.50 per share

3. Re-appointment of Mr. Dilip R Shah as Non-Executive Director

Special Business:

4. Payment of remuneration to Ms. Janki R Shah exceeding 50% of total non-executive director remuneration

5. Continuation of remuneration to Ms. Janki R Shah (₹62 lakhs per annum for 3 years from April 2027)

6. Continuation of remuneration to Mr. Saurabh Mittal (₹86 lakhs per annum for 3 years from October 2026)

7. Consultancy fees to M/s Mercury Marketing & Consulting Services (₹50 lakhs)

8. Continuation of Mr. Jayantilal Raval as Independent Director beyond age 75

9. Ratification of cost auditor remuneration (₹43,000 for FY 2026-27)

Injectable Manufacturing Facility: Commenced development of new manufacturing facility at Jarod unit with estimated project cost of ₹30 crores and annual capacity of 75 million units
Export Focus: Significant growth in export business (18.62% growth) with focus on expanding international presence
Therapeutic Focus: Continued emphasis on Gynecology and Pediatrics segments
Operational Efficiency: Improvement in operating profit margin to 14.12% from 10.61% in previous year

SEBI Compliance: Filed annual report under Regulation 34(1) of SEBI LODR
IEPF Transfer: Transferred 1,600 equity shares of 13 members and unclaimed dividend of ₹91,497 to IEPF pertaining to FY 2017-18
Compound Application: Filed compounding application before NCLT for alleged offences under Section 134 of Companies Act, 2013 for FY 2014-15 and 2015-16
Auditors: Statutory Auditors: M/s Naresh & Co.; Secretarial Auditors: M/s Dholakia & Associates LLP; Cost Auditors: M/s V.M. Patel & Associates

Key transactions approved:

Remuneration to Ms. Janki R Shah: ₹18.22 lakhs (FY26 actual) and ₹62 lakhs per annum (proposed)
Remuneration to Mr. Paresh Mistry: ₹16.06 lakhs (FY26)
Consultancy services to Mercury Marketing & Consulting Services: ₹30 lakhs (FY26)
Lease rent to Mercury Antibiotics LLP: ₹72 lakhs (FY26)
Sales to JAS Healthcare Inc.: ₹591.20 lakhs (FY26)

Compliance with SEBI LODR regulations and Companies Act, 2013
All committees (Audit, Nomination & Remuneration, Stakeholder Relationship, CSR) functional
Whistle Blower Policy and Prevention of Sexual Harassment Policy in place
No material related party transactions without approval